Janus kinase inhibition in juvenile idiopathic arthritis
- PMID: 37423229
- DOI: 10.1016/S0140-6736(23)01134-0
Janus kinase inhibition in juvenile idiopathic arthritis
Conflict of interest statement
RQC declares consulting fees for Sobi in regard to the use of anakinra in clinical trials to treat macrophage activation syndrome; textbook royalties from Springer; speaker fees from Lilly, Sobi, MedStudy, and Arthros Rheum; and consulting or advisory fees from Sironax and CareerPhysician. RQC also serves on adjudication committees and has received personal fees to establish episodes of macrophage activation syndrome among patients enrolled in clinical trials (funded by Pfizer and AbbVie) for therapeutics used to treat juvenile idiopathic arthritis. RQC holds a patent on detecting rare long non-coding RNA mutations in people with COVID-19 unrelated to the content of this Comment. ECR declares no competing interests.
Comment on
-
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423231 Clinical Trial.
Similar articles
-
Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report.Ocul Immunol Inflamm. 2023 Jul;31(5):1079-1080. doi: 10.1080/09273948.2022.2069128. Epub 2022 May 19. Ocul Immunol Inflamm. 2023. PMID: 35587645
-
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.Clin Rheumatol. 2020 Mar;39(3):847-851. doi: 10.1007/s10067-019-04875-w. Epub 2020 Jan 2. Clin Rheumatol. 2020. PMID: 31897953
-
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9. Lancet. 2021. PMID: 34767764 Clinical Trial.
-
JAK Inhibitors for the Treatment of Pediatric Alopecia Areata.J Investig Dermatol Symp Proc. 2020 Nov;20(1):S31-S36. doi: 10.1016/j.jisp.2020.04.005. J Investig Dermatol Symp Proc. 2020. PMID: 33099381 Review.
-
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).Rheumatology (Oxford). 2022 Mar 2;61(3):926-935. doi: 10.1093/rheumatology/keab673. Rheumatology (Oxford). 2022. PMID: 34459891 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical